GDF15 and risk heterogeneity within the hypoinflammatory phenotype

In a scientific correspondence published in the journal Critical Care, researchers Yuan Shen and Yunchao Zhang evaluate whether circulating concentrations of growth differentiation factor 15 can reveal meaningful prognostic differences among patients with acute respiratory distress syndrome who are classified under the hypoinflammatory phenotype. The communication responds directly to recent research led by Alipanah-Lechner and colleagues, who integrated data across multiple patient cohorts and molecular profiling datasets to demonstrate clear links between elevated GDF15, increased mortality, and metabolic stress. By expanding on established inflammatory phenotyping in acute respiratory distress syndrome, the original investigators proposed GDF15 as a candidate enrichment biomarker. However, this interpretation immediately raises an important operational question for clinical researchers: determining the precise clinical subpopulation where such complementary biological information offers the greatest practical utility.

According to Shen and Zhang, one particularly informative patient group consists of individuals who are formally classified as hypoinflammatory despite exhibiting substantially elevated concentrations of GDF15. Re-evaluating data from the CLOVERS trial, the authors observe that ninety of one hundred and fifty patients, representing sixty percent of all individuals in the highest GDF15 quartile, were categorized within the hypoinflammatory phenotype. A comparable pattern emerged within the FACTT clinical trial cohort, where forty-two of one hundred patients, or forty-two percent of those assigned to the highest GDF15 quartile, also fell into the hypoinflammatory classification.

The predictive value of incorporating GDF15 into current stratification models is further supported by statistical metrics derived from the original study. Specifically, adding GDF15 quartile classifications to standard phenotype categories increased the apparent area under the receiver operating characteristic curve for mortality from 0.646 to 0.741 in the CLOVERS trial cohort. Although Shen and Zhang point out that these observed proportions inherently depend on underlying phenotype prevalence and that the resulting areas under the curve represent in-sample statistical estimates, they argue that the combined findings provide compelling motivation to investigate risk heterogeneity within the hypoinflammatory group rather than treating these patients as a uniform clinical population.

The authors emphasize that elevated GDF15 concentrations may pinpoint patients whose physiological burden, including organ stress or metabolic stress, remains incompletely captured by inflammatory subphenotyping alone. At the same time, Shen and Zhang stress that this apparent biological discordance requires thorough empirical characterization before it can be formally interpreted as defining a distinct biological subgroup. From a clinical perspective, the decisive research question is whether elevated GDF15 in hypoinflammatory patients consistently identifies both an incremental risk of mortality and an underlying, measurable metabolic signature that distinguishes them from other hypoinflammatory individuals.

To rigorously establish the prognostic contribution of the biomarker, Shen and Zhang recommend building upon phenotype-stratified analyses by examining ninety-day mortality risks across continuous GDF15 concentrations specifically within hypoinflammatory patients. They specify that these risk calculations should report explicit confidence intervals and incorporate adjustments for key confounding factors, including patient age, biological sex, and acute illness severity. Conducting these multivariable adjustments would determine whether continuous GDF15 measurements offer independent predictive power, thereby clarifying the precise prognostic value added by the biomarker beyond conventional clinical and demographic variables.

In parallel, addressing the biological dimension of this heterogeneity requires examining paired molecular data wherever available. Shen and Zhang propose investigating the within-phenotype association between GDF15 levels and Factor 2, a previously documented molecular signature characterized by hepatic dysfunction, immune dysfunction, and impaired fatty acid beta-oxidation. Evaluating whether GDF15 correlates with Factor 2 specifically within hypoinflammatory patients would help researchers distinguish general prognostic risk information from verifiable evidence of a distinct metabolic state, clarifying whether the biomarker reflects a specific metabolic pathophysiology.

If subsequent investigations demonstrate both excess mortality risk and a corresponding metabolic signature, select hypoinflammatory patients could merit consideration for future clinical trials designed to evaluate therapies targeting those specific metabolic pathways. Quantifying event rates and the overall proportion of eligible patients within this subgroup would provide concrete parameters for prognostic enrichment strategies in clinical trial design. Although therapeutic responsiveness would remain an independent question requiring prospective evaluation, the authors conclude that determining whether GDF15 uncovers clinically relevant metabolic risk within the hypoinflammatory phenotype constitutes a critical and focused next step for the field.

Subject of Research: Prognostic biomarker evaluation in hypoinflammatory acute respiratory distress syndrome

Article Title: GDF15 and risk heterogeneity within the hypoinflammatory phenotype

Article References: Shen, Y., & Zhang, Y. (2026). GDF15 and risk heterogeneity within the hypoinflammatory phenotype. Critical Care, 30(1), Article 544. https://doi.org/10.1186/s13054-026-06406-x

Image Credits: AI Generated

DOI: 10.1186/s13054-026-06406-x

Keywords: acute respiratory distress syndrome, GDF15, biomarkers, hypoinflammatory phenotype, prognostic enrichment, critical care, metabolic stress, clinical trials, risk, heterogeneity, within, hypoinflammatory